X0206 3 2022-01-06 0 0001658551 Amylyx Pharmaceuticals, Inc. AMLX 0001920501 ALS Invest 1 B.V. C/O EERSTE WETERINGDWARSSTRAAT 54E AMSTERDAM P7 1017 TP NETHERLANDS 0 0 1 0 Series A Preferred Stock Common Stock 1129386 D Series B Preferred Stock Common Stock 4826503 D Each share of Series A and Series B preferred stock (collectively the "Preferred Stock") is convertible on a one-for-one basis into Common Stock at any time at the election of the Reporting Person and will automatically convert upon the closing of the Issuer's initial public offering into the number of shares of the Issuer's Common Stock shown in column 3 without payment or further consideration. The Preferred Stock has no expiration date. The Reporting Person is managed by SUNU Ventures BV. Felix-Andre von Coerper is the sole corporate director of SUNU Ventures BV and has voting and dispositive power with respect to the securities held by the Reporting Person. /s/ Felix-Andre von Coerper 2022-05-05